GEFITINIB | ASTRAZENECA | ||
250MG | |||
No | No | ||
2017-May-05 | Expired | ||
None | None | ||
None | No | ||
IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. |
0 | 0 | 0 |
Total Other Developers | 4 |
---|
Drugs with Suitability | No |
---|
250MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com